A cost-effectiveness study recently found that the combination of a non-selective NSAID and a proton pump inhibitor (PPI) is a more cost-effective treatment option than a COX-2 selective NSAID alone ...

For this serious adverse-event outcome, rofecoxib showed a significant benefit 3 and celecoxib showed a trend toward a benefit. 4, 5 However, a more comprehensive analysis of these trials suggests ...

Patients on non-selective nonsteroidal anti-inflammatory drugs (NSAIDs) or COX-2-selective NSAIDs, have reduced risk of gastric ulcers by taking NEXIUM® (esomeprazole magnesium).

BAE: Bovine aortic endothelial; RHP: Recombinant human protein. NSAIDs variably inhibit prostaglandin H synthase (COX). COX-2 was cloned in 1991, and it was subsequently established that COX-1 ...

The use of COX-2 selective inhibitors reduces the risk of upper gastrointestinal clinical events, compared with NSAIDs, in patients taking PPIs or low-dose aspirin; however, this result was driven ...

THE LAUNCH OF THE CYCLOOXYGENASE-2 (COX-2) selective NSAIDs was based on 2 hypotheses: (1) the major adverse effects limiting the usefulness of nonselective NSAIDs are gastrointestinal in nature and ...

The development of COX-2 inhibitors promised to achieve the benefits of NSAIDs without gastrointestinal complications. Although clinical outcome studies have demonstrated a reduction in ulcer ...

NSAIDs stop proteins called cyclooxygenase, known as COX, and fall into two classes: “selective” COX-2 inhibitors (celecoxib, etoricoxib, or rofecoxib) and “nonselective” COX-1/COX-2 ...

Defining the COX Inhibitor Selectivity of NSAIDs: Implications for Understanding Toxicity Kathleen M Knights; Arduino A Mangoni; John O Miners Disclosures Expert Rev Clin Pharmacol. 2010;3 (6):769 ...

A newer class of NSAIDS called COX-2 inhibitors cause fewer gastrointestinal side-effects such as ulcers and stomach bleedingthan other NSAIDs such as Aspirin and ibuprofen.